December 2010 | OncologyLive

ASH 2010: Large International Study Backs Use of Imatinib in Adults With Ph ALL

March 10, 2011

Imatinib (Gleevec) improves the ability to proceed with allogeneic stem cell transplantation and improves 5-year overall survival (OS) when used as induction therapy in patients with Philadelphia chromosome positive (Ph ) acute lymphoblastic leukemia

ASH 2010: Ponatinib Inhibits Mutations That Block Treatment Paths for CML, ALL, and AML

March 10, 2011

An investigational pan-BCR-ABL inhibitor designed to inhibit the entire spectrum of mutations responsible for resistance to drugs such as imatinib (Gleevec) and its cousins nilotinib (Tasigna) and dasatinib (Sprycel) appears to fulfill its promise.

NCCN Launches Consumer-Friendly Versions

March 09, 2011

NCCN Launches Consumer-Friendly Versions of Guideline Publications Breast cancer and non-small cell lung cancer are the inaugural entries in a new series of publications the National Comprehensive Cancer Network (NCCN) is rolling out in the coming months.

Modified Herpes Virus to Be Tested in Sarcoma Patients

March 09, 2011

The FDA has awarded a $600,000 grant for a phase I clinical trial of a genetically reprogrammed herpes simplex virus in young cancer patients with relapsed non-central nervous system (CNS) solid tumors such as sarcomas and neuroblastomas.

Lung Cancer Screening Test Raises Hopes and Sets Stage for Discussion of Guidelines

March 09, 2011

Lung Cancer Screening Test Raises Hopes and Sets Stage for Discussion of Guidelines The Lung Cancer Alliance is pressing for a full discussion about the guidance on whether people at high risk for lung cancer should undergo screening

Denosumab Wins Drug Award

March 09, 2011

At the 6th Annual Scrip Awards, featuring more than 500 representatives from the pharmaceutical industry, Amgen received the Best New Drug award for denosumab, the first approved inhibitor of RANK ligand.

Taking a Bow

March 09, 2011

California Researchers Receive Highest Honors From ASTRO Two prominent California-based radiation oncologists are the recipients of Gold Medal awards from the American Society for Radiation Oncology (ASTRO) this year.

FDA Approves Denosumab to Fight Cancer Bone Injuries

March 09, 2011

Denosumab, a monoclonal antibody that has proved effective in preventing bone fractures and bone pain for patients whose cancer has metastasized and damaged the bone, won approval from the FDA after a 6-month priority review.

Oncology Community Must Guide Public on Gene Testing Nuances

March 08, 2011

The genuine revolution in our understanding of the genetic basis of malignant disease has led to a corresponding interest in defining the risk of developing a particular disease for both individuals and specific populations.

ASH 2010: Brentuximab Showing Promise as Hodgkin Lymphoma Therapy

March 08, 2011

An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a phase II study of younger patients with relapsed or refractory Hodgkin lymphoma (HL) who had no other treatment options

The 40-Year War

March 08, 2011

It was 40 years ago in January that Richard Nixon, still grappling with the Vietnam War and not yet overwhelmed by scandal, stood before Congress to deliver the State of the Union address and declared a bold new goal for the nation.

Making Their Own Way

March 08, 2011

When Patricia Hardenbergh, MD, left the academic environment of Duke University Medical Center in North Carolina to become director of radiation oncology in a mountain town in Colorado about 10 years ago, it was more than simply an 1800-mile change of scenery.